Jessica Lee, MD
Ophthalmology · Hauppauge, NYNPI 1083906747
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.5%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Regeneron at 58.8% of the total. 2025 is the largest year on record at $6,941, more than ten times the $321 reported in 2019.
Across 107 payments — averaging $95.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$6K
- Alimera Sciences, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$828
- Genentech USA, Inc.$586
- AbbVie$270
- Alcon$264
- plus $1K from 15 others
What the payments were for
- Consulting fees$5,64055%
- Speaking & faculty fees$1,20012%
- Travel & lodging$2843%
- Food & beverage$3,02530%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 9 | $5,979 |
| Alimera Sciences, Inc. | 2 | $1,223 |
| Regeneron Healthcare Solutions, Inc. | 33 | $828 |
| Genentech USA, Inc. | 28 | $586 |
| AbbVie(2 entities) | 10 | $270 |
| Alcon | 3 | $264 |
| Apellis Pharmaceuticals, Inc. | 6 | $238 |
| Glaukos Corporation | 1 | $161 |
| Novartis | 2 | $137 |
| LKC Technologies, Inc. | 1 | $130 |
| Coherus Oncology, Inc. | 2 | $89 |
| Sandoz | 1 | $36 |
| Harrow Eye, LLC | 1 | $35 |
| Coopervision Inc. | 1 | $33 |
| Genentech, Inc. | 1 | $32 |
| Eyepoint US, Inc. | 1 | $25 |
| Biogen | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Bausch & Lomb Americas Inc. | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Axogen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA HD$6,023
- Iluvien$1,200
- iDoseTR$161
- EYLEA$149
- Syfovre$115
- AcrySof IQ PanOptix UV IOL$106
- AcrySof IQ VIVITY$106
How this compares
$10,168 in reported general payments places this provider in the 85th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 139 | $6,269 |
| Bromfenac Sodium | 40 | $5,304 |
| Ketorolac Tromethamine | 45 | $1,498 |
| Ofloxacin | 70 | $1,135 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 42 | $632 |
| Latanoprost | 34 | $412 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Hauppauge
- David RubaltelliBrooklyn$8.9M
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Eric DonnenfeldGarden City$1.4M
- Marguerite McDonaldOceanside$893K
- Joshua YoungNew York$814K
- David KleinmanRochester$730K
- Jonathan JonischGreat Neck$726K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.